Perspective: effect of rosiglitazone on cardiovascular outcomes.
Nissen
Steven E
SE
Department of Cardiovascular Medicine, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA. nissens@ccf.org
D002318:Cardiovascular Diseases / Q000401:mortality*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D009203:Myocardial Infarction / Q000139:chemically induced* / Q000453:epidemiology; D016017:Odds Ratio; D047495:PPAR gamma / Q000819:agonists*; D018570:Risk Assessment; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects*
D007004:Hypoglycemic Agents; D047495:PPAR gamma; D045162:Thiazolidinediones; D000077154:Rosiglitazone